Journal of the American Pharmacists Association
Volume 49, Issue 5, Supplement 1, September–October 2009, Pages S16-S29
REVIEWSDifferential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors
References (142)
- et al.
Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999–2004
Ann Epidemiol.
(2008) The [pre-] history of the incretin concept
Regul Pept.
(2005)- et al.
The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects
Regul Pept.
(1994) - et al.
Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men
Am J Clin Nutr.
(1998) - et al.
Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut
FEBS Lett.
(1987) - et al.
Glucagon-like peptide-1 7-36: a physiological incretin in man
Lancet.
(1987) - et al.
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Lancet.
(2006) - et al.
Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas
J Biol Chem.
(1992) - et al.
Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard
J Biol Chem.
(1997) - et al.
Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells
J Biol Chem.
(1993)
The biology of incretin hormones
Cell Metab.
(2006)
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
Lancet.
(2009)
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
Lancet.
(2008)
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
Lancet.
(2009)
Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study
Clin Ther.
(2008)
Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes
Diabetes Res Clin Pract.
(2007)
Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin
Endocr Pract.
(2007)
Efficacy and safety of incretin-based therapies: clinical trial data
J Am Pharm Assoc.
(2009)
Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue
Mol Cell Endocrinol.
(2009)
The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro
Biochem Biophys Res Commun.
(2005)
Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro
Biomaterials.
(1999)
10-year follow-up of intensive glucose control in type 2 diabetes
N Engl J Med.
(2008)
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
N Engl J Med.
(2008)
Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999–2002: the National Health and Nutrition Examination Survey
Diabetes Care.
(2006)
Prospective Diabetes Study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease
Diabetes.
(1995)
Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). U.K. Prospective Diabetes Study (UKPDS) Group
JAMA.
(1999)
Weight gain associated with intensive therapy in the diabetes control and complications trial
Diabetes Care.
(1988)
Intensified treatment of type 2 diabetes: positive effects on blood pressure, but not glycaemic control
QJM.
(2003)
Clinical inertia contributes to poor diabetes control in a primary care setting
Diabetes Educ.
(2005)
The physiology of incretin hormones and the basis for DPP-4 inhibitors
Diabetes Educ.
(2007)
Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2
Am J Physiol.
(1999)
Reduced incretin effect in type 2 (non–insulin-dependent) diabetes
Diabetologia.
(1986)
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus
J Clin Invest.
(1993)
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
J Clin Endocrinol Metab.
(2001)
Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients
Diabetes.
(2001)
Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine
J Clin Invest.
(1991)
Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes
Diabetes
(2004)
Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects
Diabetes
(2004)
Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients
Diabetologia.
(2002)
Near-normalisa-tion of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NI-DDM
Diabetologia.
(1997)
Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men
Int J Obes Relat Metab Disord.
(1999)
Glucagon-like peptide-1 (GLP-1): a gut hormone of potential interest in the treatment of diabetes
Bioessays.
(1998)
Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man
Dig Dis Sci.
(1993)
Glucagon-like peptide-1: a major regulator of pancreatic beta-cell function
Eur J Endocrinol.
(2000)
Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats
Diabetes.
(1999)
Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets
Endocrinology.
(2003)
Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo
J Clin Endocrinol Metab.
(1995)
Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum
Eur J Biochem.
(1993)
Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects
J Clin Endocrinol Metab.
(2003)
Unraveling the science of incretin biology
Am J Med.
(2009)
Cited by (0)
Disclosure: Research support from Novartis and Merck. Otherwise, the author declares no conflicts of interest or financial interests in any product or service mentioned in this article, including grants, employment, gifts, stock holdings, or honoraria.
Acknowledgment: AdelphiEden Health Communications and Jacki Gordon, PhD for medical editorial services.
Funding: Publication of the supplement to JAPhA made possible through an educational grant from Novo Nordisk Inc.
Copyright © 2018 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.